cardiomyocytes

[Current Opinion in Cardiology] The authors describe the latest advances in cell therapy, biomaterials and 3D bioprinting for the treatment of cardiovascular disease.

[Proceedings of the National Academy of Sciences of the United States of America] Scientists generated reactive oxygen species (ROS)-sensitive fluorescent sensors targeted to different subnuclear compartments in neonatal rat ventricular cardiomyocytes, which allowed them to determine the spatial localization of ROS in cardiomyocyte nuclei upon manipulation of mitochondrial respiration.

[Nature Reviews Cardiology] The authors provide an overview of state-of-the-art studies, challenges that have not yet been overcome and perspectives on cardiac tissue engineering.

[Scientific Reports] Scientists developed a homozygous NaV1.5 KO iPSC line able to differentiate into cardiomyocytes with CRISPR/Cas9 tool. The NaV1.5 KO iPSC-cardiomyocytes exhibited an organized contractile apparatus, spontaneous contractile activity, and electrophysiological recordings confirmed the major reduction in total Na+ currents.

[Molecular Therapy-Nucleic Acids] The authors indicated that CMDL-1 may have played an anti-apoptotic role in doxorubicin (DOX) cardiotoxicity by regulating Drp1 S637 phosphorylation. Thus, CMDL-1 may have served as a potential therapeutic target in DOX cardiotoxicity.

[Nature Biomedical Engineering] Investigators reported the reprogramming of mouse tail-tip fibroblasts simultaneously into cells resembling cardiomyocytes, endothelial cells or smooth muscle cells using the microRNA mimic miR-208b-3p, ascorbic acid and bone morphogenetic protein 4, as well as the formation of tissue-like structures formed by the directly reprogrammed cells.